Abstract 2747: Chaperonin-containing TCP-1 promotes the release of exosomes from prostate and breast cancer cells
Authors: Annette R. Khaled, Lam Truong, Colten Frank, Carolyn Dang, James Velazquez, Priya Gopalan, Sally Litherland
Journal: Cancer Research (2024)

Abstract Coping with cancer recurrence and assessing metastatic risk are challenges for cancer patients that could be addressed with an effective diagnostic predictor. Exosomes, a subpopulation of extracellular vesicles released by tumor cells, can promote distal metastatic site development and could have promising diagnostic applications. However, the mechanisms controlling exosome secretion by cancer cells remain to be determined, which impedes clinical development. The actions of protein-folding chaperones could facilitate tumor exosome formation, payload loading, and extracellular release. Protein folding complexes link the expression of tumor-promoting oncogenes with the proteins driving oncogenic cancer behavior. Of these, the eukaryotic type II chaperonin, Chaperonin-Containing TCP-1 (CCT), folds many of the oncoproteins (e.g., KRAS, MYC, CDKs, STAT3, etc.) responsible for cancer growth and invasion. CCT is a complex machine composed of eight subunits, each encoded by a unique gene (cct1-8), which folds proteins in an ATP-dependent fashion. We and others showed that CCT is upregulated in breast, lung, and prostate cancer cells as well as neuroblastoma, leading to alterations in apoptosis, migration, cell morphology, and proliferation. Using T47D breast cancer and PC3 and 22rV1 prostate cancer cells, we exogenously expressed or depleted the second subunit of the CCT complex (CCT2). With these cells, we isolated exosomes from culture media by membrane-based affinity binding and examined exosomal RNA and protein content. In exosomes from prostate and breast cancer cells, we found abundant CCT2 subunit mRNA and protein in CD63+ exosomes ranging from 50 to 120 microns in size. When CCT2 was exogenously expressed in breast and prostate cancer cells, CCT2 mRNA and protein were higher in exosomes than other CCT subunits, and CCT2 was randomly distributed throughout the size range of exosomes. Of interest, an increase in CD63+ small exosomes (50-75 microns) was evident in cancer cells exogenously expressing CCT2 compared to mock-transfected and parental controls, suggesting a role for CCT2 in the exosomal secretory pathway. FACS-sorted CD63+ exosomes subjected to mass spectrometry yielded distinct protein content based on CCT2 expression. These findings are the first report of CCT2 driving exosome secretion in cancer cells and suggest that exosomes containing CCT2 RNA and protein are associated with metastatic potential. Exosomal CCT2 thus represents a promising diagnostic indicator for a liquid biopsy approach to monitor cancer recurrence and metastasis. Citation Format: Annette R. Khaled, Lam Truong, Colten Frank, Carolyn Dang, James Velazquez, Priya Gopalan, Sally Litherland. Chaperonin-containing TCP-1 promotes the release of exosomes from prostate and breast cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2747.